Rescue of hypoxia-inducible factor-1α-deficient tumor growth by wild-type cells is independent of vascular endothelial growth factor

Cancer Research

Volumn 62, Issue 10, 2002, Pages 2962-2970

  Höpfl, Gisele ^a   Wenger, Roland H ^c   Ziegler, Urs ^a   Stallmach, Thomas ^b   Gardelle, Olivier ^a   Achermann, Roger ^a   Wergin, Melanie ^a   Kaser Hotz, Barbara ^a   Saunders, H Mark ^d   Williams, Kaye J ^e   Stratford, Ian J ^e   Gassmann, Max ^a   Desbaillets, Isabelle ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c Medical University of Lübeck   (Switzerland)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; VASCULOTROPIN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENOTYPE; HYPOXIA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; STEM CELL; TERATOCARCINOMA; TUMOR GROWTH; VASCULARIZATION;

ANIMALS; APOPTOSIS; CELL DIFFERENTIATION; CELL DIVISION; CELL HYPOXIA; CELL TRANSFORMATION, NEOPLASTIC; ENDOTHELIAL GROWTH FACTORS; FEMALE; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LYMPHOKINES; MICE; MICE, INBRED BALB C; MICE, NUDE; RNA, MESSENGER; STEM CELLS; TERATOCARCINOMA; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0037093107     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
2. The hypoxic cell: A target for selective cancer therapy: 18th Bruce F. Cain Memorial Award lecture
3. Hypoxia in human soft tissue sarcomas: Adverse impact on survival and no association with p53 mutations
4. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix
5. Bioreductive drugs into the next millennium
6. Exploiting the hypoxic cancer cell: Mechanisms and therapeutic strategies
7. 2 tension
8. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1-α regulates the VEGF expression and is potentially involved in lung and vascular development
9. Molecular characterization and chromosomal localization of a third a-class hypoxia-inducible subunit, HIF-3α
10. Induction of HIF-1α in response to hypoxia is instantaneous
11. HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia
12. Induction and nuclear translocation of hypoxia-inducible factor-1 (HIF-1): Heterodimerization with ARNT is not necessary for nuclear accumulation of HIF-1α
13. Dissecting hypoxia-dependent and hypoxia-independent steps in the HIF-1α activation cascade: Implications for HIF-1α gene therapy
14. Mammalian oxygen sensing, signalling, and gene regulation
15. Transcription factor HIF-1 is a necessary mediator of the Pasteur effect in mammalian cells
16. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function
17. Loss of PTEN facilitates HIF-1-mediated gene expression
18. VHL takes HIF's breath away
19. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression
20. 2-regulated prolyl hydroxylation
21. 2 sensing
22. Ubiquitination of hypoxia-inducible factor requires direct binding to the β-domain of the von Hippel-Lindau protein
23. Up-regulation of vascular endothelial growth factor in stromal cells of hemangioblastomas is correlated with up-regulation of the transcription factor HRF/HIF-2α
24. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases
25. Levels of hypoxia-inducible factor-1α during breast carcinogenesis
26. Overexpression of hypoxia-inducible factor 1α is a marker for an unfavorable prognosis in early-stage invasive cervical cancer
27. HIF-1α is required for solid tumor formation and embryonic vascularization
28. Suppression of tumor growth through disruption of hypoxia-inducible transcription
29. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation, and tumour angiogenesis
30. Targeting gene expression to hypoxic tumor cells
31. Development of a hypoxia-responsive vector for tumor-specific gene therapy
32. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy
33. Differentiating embryonic stem cells as an in vitro model of early erythropoiesis
34. The role of aggregation in embryonal carcinoma cell differentiation
35. The mouse gene for hypoxia-inducible factor-1 alpha-genomic organization, expression and characterization of an alternative first exon and 5′ flanking sequence
36. Dicistronic targeting constructs: Reporters and modifiers of mammalian gene expression
37. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1
38. Nucleotide sequence, chromosomal assignment and mRNA expression of mouse hypoxia-inducible factor-1α
39. General applicability of chicken egg yolk antibodies: The performance of IgY immunoglobulins raised against the hypoxia-inducible factor 1α
40. Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: Effects of VEGF-toxin conjugate on tumor microvessel density
41. Use of power Doppler ultrasound-guided biopsies to locate regions of tumour hypoxia
42. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations
43. Oxygen tension measurements of tumors growing in mice
44. Transactivation and inhibitory domains of hypoxia-inducible factor 1α. Modulation of transcriptional activity by oxygen tension
45. Myeloid leukaemia inhibitory factor maintains the developmental potential of embryonic stem cells
46. Embryoid bodies: An in vitro model of mouse embryogenesis
47. Quantitative vascularity of breast masses by Doppler imaging: Regional variations and diagnostic implications
48. Factors affecting topotecan-induced programmed cell death: Adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose) polymerase
49. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
50. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
51. Hypoxia-inducible factor-1α is a positive factor in solid tumor growth
52. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
53. Heterogeneous vascular dependence of tumor cell populations
54. Up-regulation of hypoxia-inducible factor-1α is not sufficient for hypoxic/anoxic p53 induction
55. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes
56. Posttranscriptional regulation of vascular endothelial growth factor by hypoxia
57. Tumor induction of VEGF promoter activity in stromal cells
58. 2 homeostasis by hypoxia-inducible factor 1α
59. Defective vascularization of HIF-1α-null embryos is not associated with VEGF deficiency but with mesenchymal cell death